19 EGFR mutation rate in TRANSCRIPT: A study to assess the incidence of EGFR mutations in UK NSCLC patients with newly diagnosed locally advanced or metastatic disease. A single arm, open label study

A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations: Erratum

Medicine ◽

10.1097/md.0000000000028585 ◽

2022 ◽

Vol 101 (2) ◽

pp. e28585

Keyword(s):

Combination Therapy ◽

Locally Advanced ◽

Egfr Mutations ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Metastatic Nsclc ◽

Nsclc Patients

A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations

Medicine ◽

10.1097/md.0000000000023455 ◽

2020 ◽

Vol 99 (49) ◽

pp. e23455

Author(s):

Si-Yeon Song ◽

Su-Jeong Ha ◽

Ji-Hye Park ◽

So-Jung Park ◽

Seong Hoon Shin ◽

...

Keyword(s):

Combination Therapy ◽

Locally Advanced ◽

Egfr Mutations ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Metastatic Nsclc ◽

Nsclc Patients

An Open-label Study of the Safety and Efficacy of Tag-7 Gene-modified Tumor Cell-based Vaccine in Patients With Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer

Case Medical Research ◽

10.31525/ct1-nct04180774 ◽

2019 ◽

Author(s):

Keyword(s):

Malignant Melanoma ◽

Tumor Cell ◽

Renal Cell ◽

Cell Cancer ◽

Locally Advanced ◽

Metastatic Malignant Melanoma ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China

Annals of Hematology ◽

10.1007/s00277-018-3488-1 ◽

2018 ◽

Vol 98 (1) ◽

pp. 143-150 ◽

Author(s):

Yan Zhang ◽

Wei Zhang ◽

Jian Li ◽

Minghui Duan ◽

Bing Han ◽

...

Keyword(s):

T Cell ◽

Cell Lymphoma ◽

T Cell Lymphoma ◽

Phase 2 ◽

Newly Diagnosed ◽

Single Center ◽

Open Label ◽

Peripheral T Cell Lymphoma ◽

Open Label Study ◽

Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

The Lancet Haematology ◽

10.1016/s2352-3026(20)30323-9 ◽

2020 ◽

Vol 7 (12) ◽

pp. e861-e873 ◽

Author(s):

Paola Tacchetti ◽

Lucia Pantani ◽

Francesca Patriarca ◽

Maria Teresa Petrucci ◽

Elena Zamagni ◽

...

Keyword(s):

Haematopoietic Stem Cell Transplantation ◽

Haematopoietic Stem Cell ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Long Term Follow Up

ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

Neuro-Oncology ◽

10.1093/neuonc/noy148.073 ◽

2018 ◽

Vol 20 (suppl_6) ◽

pp. vi20-vi20

Author(s):

Daniela A Bota ◽

Santosh Kesari ◽

David Piccioni ◽

Dawit Aregawi ◽

Patrick Roth ◽

...

Keyword(s):

Malignant Glioma ◽

Phase 1 ◽

Newly Diagnosed ◽

Open Label ◽

Who Grade ◽

Open Label Study ◽

ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.05.366 ◽

2020 ◽

Vol 159 ◽

pp. 221

Author(s):

C. Marth ◽

C. Vulsteke ◽

M.J.R. Rubio ◽

V. Makker ◽

E.I. Braicu ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase Iii ◽

Newly Diagnosed ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Recurrent Endometrial Cancer

A phase I, open-label study (EGF 100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Radiotherapy and Oncology ◽

10.1016/s0167-8140(07)80091-0 ◽

2007 ◽

Vol 82 ◽

pp. S30 ◽

Author(s):

I. El-Hariry ◽

K. Harrington ◽

J. Bourhis ◽

C. Holford

Keyword(s):

Squamous Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma ◽

Open Label ◽

Open Label Study ◽

Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-016-1052-3 ◽

2016 ◽

Vol 22 (1) ◽

pp. 79-79 ◽

Author(s):

Noboru Yamamoto ◽

Koichi Goto ◽

Makoto Nishio ◽

Kenichi Chikamori ◽

Toyoaki Hida ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Egfr Mutation ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Abstract P5-19-06: 4EVER - Final efficacy analysis of the phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE)

10.1158/1538-7445.sabcs14-p5-19-06 ◽

2015 ◽

Author(s):

Hans Tesch ◽

Oliver J Stoetzer ◽

Thomas Decker ◽

Christian M Kurbacher ◽

Romy Neumeister ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Locally Advanced ◽

Metastatic Breast ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Efficacy Analysis ◽

Phase Iiib ◽

Estrogen Receptor Positive